Mereo BioPharma Group Plc (MREO)
0.305
0.00 (0.00%)
USD |
NASDAQ |
Nov 12, 16:00
0.305
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Enterprise Value : 23.19M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 23.19M |
| November 11, 2026 | 23.44M |
| November 10, 2026 | 22.05M |
| November 09, 2026 | 21.60M |
| November 06, 2026 | 19.67M |
| November 05, 2026 | 19.26M |
| November 04, 2026 | 22.88M |
| November 03, 2026 | 20.95M |
| November 02, 2026 | 20.79M |
| October 30, 2026 | 20.71M |
| October 29, 2026 | 22.67M |
| October 28, 2026 | 21.91M |
| October 27, 2026 | 21.06M |
| October 26, 2026 | 18.40M |
| October 23, 2026 | 19.46M |
| October 22, 2026 | 20.38M |
| October 21, 2026 | 20.98M |
| October 20, 2026 | 21.60M |
| October 19, 2026 | 22.72M |
| October 16, 2026 | 22.87M |
| October 15, 2026 | 23.84M |
| October 14, 2026 | 23.90M |
| October 13, 2026 | 25.58M |
| October 12, 2026 | 24.81M |
| October 09, 2026 | 30.36M |
| Date | Value |
|---|---|
| October 08, 2026 | 34.40M |
| October 07, 2026 | 30.82M |
| October 06, 2026 | 30.39M |
| October 05, 2026 | 36.44M |
| October 02, 2026 | 35.13M |
| October 01, 2026 | 33.07M |
| September 30, 2026 | 38.68M |
| September 29, 2026 | 30.48M |
| September 28, 2026 | 29.97M |
| September 25, 2026 | 29.97M |
| September 24, 2026 | 24.78M |
| September 23, 2026 | 25.23M |
| September 22, 2026 | 21.40M |
| September 21, 2026 | 17.22M |
| September 18, 2026 | 19.28M |
| September 17, 2026 | 17.22M |
| September 16, 2026 | 13.37M |
| September 15, 2026 | 16.40M |
| September 14, 2026 | 15.61M |
| September 11, 2026 | 15.61M |
| September 10, 2026 | 9.955M |
| September 09, 2026 | 9.620M |
| September 08, 2026 | 11.55M |
| September 04, 2026 | 10.82M |
| September 03, 2026 | 14.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -20.99M |
| BioNTech SE | 5.828B |
| Silence Therapeutics Plc | 853.12M |
| Autolus Therapeutics Plc | 508.24M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.860M |
| Revenue (Quarterly) | 0.7996M |
| Total Expenses (Quarterly) | 6.660M |
| EPS Diluted (Quarterly) | -0.0364 |
| Gross Profit Margin (Quarterly) | 49.12% |
| Profit Margin (Quarterly) | -732.9% |
| Earnings Yield | -55.08% |
| Normalized Earnings Yield | -55.54 |